iproniazid has been researched along with clorgyline in 50 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 6 (12.00) | 18.7374 |
1990's | 1 (2.00) | 18.2507 |
2000's | 6 (12.00) | 29.6817 |
2010's | 31 (62.00) | 24.3611 |
2020's | 6 (12.00) | 2.80 |
Authors | Studies |
---|---|
Alcaro, S; Bolasco, A; Carradori, S; Chimenti, F; Chimenti, P; Cirilli, R; Ferretti, R; Granese, A; La Torre, F; Maccioni, E; Orallo, F; Ortuso, F; Secci, D; Yáñez, M | 1 |
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
Alcaro, S; Bizzarri, B; Bolasco, A; Carradori, S; Chimenti, F; Chimenti, P; Granese, A; Orallo, F; Ortuso, F; Secci, D; Yáñez, M | 1 |
Alcaro, S; Bolasco, A; Chimenti, F; Chimenti, P; Fioravanti, R; Orallo, F; Ortuso, F; Rossi, F; Secci, D; Yáñez, M | 1 |
Bizzarri, B; Bolasco, A; Carradori, S; Chimenti, F; Chimenti, P; Granese, A; Orallo, F; Secci, D; Yáñez, M | 1 |
Alcaro, S; Bolasco, A; Chimenti, F; Chimenti, P; Cirilli, R; Ferretti, R; Fioravanti, R; Orallo, F; Ortuso, F; Rossi, F; Sanna, ML; Secci, D; Yáñez, M | 1 |
Alcaro, S; Borges, F; Gaspar, A; Milhazes, N; Orallo, F; Ortuso, F; Uriarte, E; Yáñez, M | 1 |
Alcaro, S; Bolasco, A; Cardia, MC; Carradori, S; Chimenti, F; Chimenti, P; Cirilli, R; Distinto, S; Ferretti, R; Granese, A; Kirchmair, J; Langer, T; Maccioni, E; Orallo, F; Ortuso, F; Secci, D; Yáñez, M | 1 |
Alcaro, S; Bolasco, A; Carradori, S; Chimenti, F; Chimenti, P; Granese, A; Orallo, F; Ortuso, F; Secci, D; Yáñez, M | 1 |
Alcaro, S; Cardia, MC; Costa, G; Distinto, S; Maccioni, E; Meleddu, R; Orallo, F; Sanna, ML; Secci, D; Vigo, S; Yanez, M | 1 |
Bolasco, A; Carradori, S; Chimenti, F; Chimenti, P; Cirilli, R; Gallinella, B; Granese, A; Orallo, F; Sanna, ML; Secci, D; Yáñez, M | 1 |
Alcaro, S; Bolasco, A; Fioravanti, R; Manna, F; Orallo, F; Ortuso, F; Rossi, F; Vitali, A; Yáñez, M | 1 |
Alcaro, S; Bolasco, A; Desideri, N; Fioravanti, R; Monaco, LP; Orallo, F; Ortuso, F; Yáñez, M | 1 |
Alcaro, S; Bolasco, A; Carradori, S; Chimenti, P; Ortuso, F; Secci, D; Yáñez, M | 1 |
Escobar, M; García-Mera, X; González-Díaz, H; Prado-Prado, F; Riera-Fernandez, P; Sobarzo-Sánchez, E; Yañez, M | 1 |
Alcaro, S; Bolasco, A; Cardia, MC; Distinto, S; Gaspari, M; Kirchmair, J; Maccioni, E; Markt, P; Meleddu, R; Ortuso, F; Sanna, ML; Secci, D; Wolber, G; Yáñez, M | 1 |
Abdalla, MM; Abdelhafez, OM; Ali, HI; Amin, KM; Batran, RZ | 1 |
Bolasco, A; Carradori, S; D'Ascenzio, M; Nescatelli, R; Secci, D; Yáñez, M | 1 |
Alcaro, S; Biava, M; Desideri, N; Fioravanti, R; Ortuso, F; Proietti Monaco, L; Yáñez, M | 2 |
Biava, M; Desideri, N; Fioravanti, R; Grammatica, L; Proietti Monaco, L; Yáñez, M | 1 |
Alcaro, S; Carradori, S; Cirilli, R; D'Ascenzio, M; De Monte, C; Mannina, L; Ortuso, F; Secci, D; Sobolev, AP; Yáñez, M | 1 |
Alcaro, S; Arridu, A; Bianco, G; Cirilli, R; Cossu, P; Cottiglia, F; Distinto, S; Faggi, C; Maccioni, E; Meleddu, R; Ortuso, F; Sanna, ML; Yanez, M | 1 |
Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xiao, G | 1 |
Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Sang, Z; Su, F; Xiao, G; Yang, X; Zheng, Y | 1 |
Ai, J; Deng, Y; Li, Y; Liu, Q; Luo, L; Qiang, X; Tan, Z; Xiao, G; Yang, X | 1 |
Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Sang, Z; Su, F; Xiao, G; Xu, R; Yang, X; Zheng, Y | 1 |
Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xu, R; Yang, X; Zheng, Y | 2 |
Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Song, Q; Tan, Z; Xiao, G; Xu, R; Yang, X | 1 |
Liu, W; Ma, Q; Pan, W; Sang, Z; Wang, K; Yu, L | 1 |
Han, X; Liu, W; Ma, Q; Sang, Z; Wang, H; Wang, K; Ye, M; Yu, L | 1 |
Cao, Z; Deng, Y; Li, Y; Liu, H; Qiang, X; Song, Q; Tan, Z; Xu, R; Yang, J; Zhang, X | 1 |
Deng, Y; Li, Y; Liu, H; Song, Q; Tan, Z; Xiao, G; Xu, R; Yang, Z; Zhang, X; Zheng, Y | 1 |
Cao, Z; Deng, Y; Liu, Z; Song, Q; Tan, Z; Yang, Z; Yu, G | 1 |
Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Song, Q; Tan, Z | 1 |
Cheng, M; Guo, J; Jiang, N; Li, Q; Liang, N; Liu, J; Nong, X; Pang, C; Qin, Y; Tang, C; Tang, W; Xie, SS; Zhang, Z | 1 |
Cao, Z; Cong, S; Deng, Y; Liu, Z; Song, Q; Tan, Z; Yu, G | 1 |
Cao, Z; Deng, Y; Sang, Z; Song, Q; Tan, Z; Zhang, L | 1 |
Amoroso, R; Carradori, S; De Filippis, B; Fantacuzzi, M | 1 |
Prozialeck, WC; Vogel, WH | 1 |
Boulton, AA; Philips, SR | 1 |
Hoogenboom, LA; Kuiper, HA; Oorsprong, MB; Tomassini, O | 1 |
Fagervall, I; Ross, SB | 1 |
Erikson, JM; Prough, RA | 1 |
Ancher, JF; Benedetti, MS; Sontag, N | 1 |
Green, K; Lollis, G | 1 |
Lee, KS; Lee, MK; Lee, SS; Ro, JS | 1 |
Cano, E; Fraiz, N; Orallo, F; Yáñez, M | 1 |
Fisar, Z; Hroudová, J; Raboch, J | 1 |
1 review(s) available for iproniazid and clorgyline
Article | Year |
---|---|
Resveratrol-based compounds and neurodegeneration: Recent insight in multitarget therapy.
Topics: Humans; Neurodegenerative Diseases; Polyphenols; Resveratrol; Stilbenes; Structure-Activity Relationship | 2022 |
49 other study(ies) available for iproniazid and clorgyline
Article | Year |
---|---|
Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.
Topics: Chromatography, High Pressure Liquid; Cyclohexanones; Humans; Hydrazones; Inhibitory Concentration 50; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Stereoisomerism; Thermodynamics; Thiazoles; Thiosemicarbazones | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins.
Topics: Coumarins; Crystallography, X-Ray; Humans; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2009 |
Chalcones: a valid scaffold for monoamine oxidases inhibitors.
Topics: Chalcones; Crystallography, X-Ray; Databases, Protein; Drug Design; Humans; Inhibitory Concentration 50; Isoenzymes; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors | 2009 |
Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1H)-pyrazole derivatives.
Topics: Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pyrazoles | 2010 |
A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.
Topics: Flavanones; Flavones; Humans; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Stereoisomerism; Sulfhydryl Compounds | 2010 |
Chromone-2- and -3-carboxylic acids inhibit differently monoamine oxidases A and B.
Topics: Binding Sites; Chromones; Computer Simulation; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Isoforms | 2010 |
Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors.
Topics: Chromatography, High Pressure Liquid; Humans; Hydrazones; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship; Thiazoles | 2010 |
Investigations on the 2-thiazolylhydrazyne scaffold: synthesis and molecular modeling of selective human monoamine oxidase inhibitors.
Topics: Humans; Hydrazines; Hydrogen Peroxide; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2010 |
Synthesis of new 3-aryl-4,5-dihydropyrazole-1-carbothioamide derivatives. An investigation on their ability to inhibit monoamine oxidase.
Topics: Animals; Cell Line; Humans; Insecta; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding; Pyrazoles; Recombinant Proteins; Structure-Activity Relationship; Thioamides | 2010 |
Synthesis, stereochemical separation, and biological evaluation of selective inhibitors of human MAO-B: 1-(4-arylthiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazines.
Topics: Chromatography, High Pressure Liquid; Cyclohexanes; Humans; Hydrazines; Isoenzymes; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Stereoisomerism; Structure-Activity Relationship; Triazoles | 2010 |
Synthesis and molecular modelling studies of prenylated pyrazolines as MAO-B inhibitors.
Topics: Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Prenylation; Pyrazoles; Structure-Activity Relationship | 2010 |
Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties.
Topics: Drug Discovery; Flavonoids; Humans; Inhibitory Concentration 50; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Conformation; Substrate Specificity | 2011 |
Synthesis and selective human monoamine oxidase inhibition of 3-carbonyl, 3-acyl, and 3-carboxyhydrazido coumarin derivatives.
Topics: Coumarins; Humans; Inhibitory Concentration 50; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2011 |
2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins.
Topics: Antiprotozoal Agents; Aporphines; Databases, Factual; Humans; Ligands; Malaria, Falciparum; Markov Chains; Models, Biological; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Plasmodium falciparum; Protozoan Proteins; Quantitative Structure-Activity Relationship; Software; United States | 2011 |
Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B.
Topics: Binding Sites; Humans; Hydrazones; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Dynamics Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Protein Conformation; Structure-Activity Relationship; Tandem Mass Spectrometry; Thiazoles | 2012 |
Synthesis of new 7-oxycoumarin derivatives as potent and selective monoamine oxidase A inhibitors.
Topics: Coumarins; Hydrogen Bonding; Magnetic Resonance Spectroscopy; Mass Spectrometry; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Spectrophotometry, Infrared | 2012 |
Recent advances in the development of selective human MAO-B inhibitors: (hetero)arylidene-(4-substituted-thiazol-2-yl)hydrazines.
Topics: Dose-Response Relationship, Drug; Humans; Hydrazines; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2012 |
1,5-Diphenylpenta-2,4-dien-1-ones as potent and selective monoamine oxidase-B inhibitors.
Topics: Cells, Cultured; Curcumin; Enzyme Activation; Humans; Inhibitory Concentration 50; Models, Molecular; Monoamine Oxidase Inhibitors; Quantum Theory; Structure-Activity Relationship | 2013 |
Design, synthesis, and in vitro hMAO-B inhibitory evaluation of some 1-methyl-3,5-diphenyl-4,5-dihydro-1H-pyrazoles.
Topics: Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Humans; Molecular Structure; Monoamine Oxidase; Pyrazoles; Structure-Activity Relationship | 2013 |
Identification of the stereochemical requirements in the 4-aryl-2-cycloalkylidenhydrazinylthiazole scaffold for the design of selective human monoamine oxidase B inhibitors.
Topics: Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Design; Humans; Isoenzymes; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Stereoisomerism; Structure-Activity Relationship; Thiazoles | 2014 |
Drug design, synthesis, in vitro and in silico evaluation of selective monoaminoxidase B inhibitors based on 3-acetyl-2-dichlorophenyl-5-aryl-2,3-dihydro-1,3,4-oxadiazole chemical scaffold.
Topics: Computer Simulation; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Dynamics Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxadiazoles; Structure-Activity Relationship | 2016 |
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Blood-Brain Barrier; Chelating Agents; Copper; Humans; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Protein Aggregates; Swine | 2016 |
(E)-3-Heteroarylidenechroman-4-ones as potent and selective monoamine oxidase-B inhibitors.
Topics: Chromans; Humans; Hydrogen Bonding; Inhibitory Concentration 50; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Sensitivity and Specificity; Solvents; Structure-Activity Relationship | 2016 |
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Isoflavones; Mannich Bases; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2017 |
Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Drug Design; Electrophorus; Humans; Mannich Bases; Neuroprotective Agents; PC12 Cells; Rats | 2017 |
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Chalcones; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Rivastigmine; Structure-Activity Relationship; Swine | 2017 |
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipyrine; Benzofurans; Binding Sites; Blood-Brain Barrier; Edaravone; Humans; Hydrogen Bonding; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding; Protein Structure, Tertiary | 2017 |
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cell Line; Cholinesterase Inhibitors; Humans; Kinetics; Models, Molecular; Monoamine Oxidase Inhibitors; Thioxanthenes; Xanthones | 2017 |
Pyridoxine-resveratrol hybrids Mannich base derivatives as novel dual inhibitors of AChE and MAO-B with antioxidant and metal-chelating properties for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Chelating Agents; Cholinesterase Inhibitors; Electrophorus; Humans; Kinetics; Mannich Bases; Metals; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pyridoxine; Rats; Resveratrol; Stilbenes | 2017 |
Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Electrophorus; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quinolines; Swine | 2017 |
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzophenones; Binding Sites; Blood-Brain Barrier; Cell Survival; Cholinesterase Inhibitors; Drug Design; Humans; Hydrogen Peroxide; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Neuroprotective Agents; PC12 Cells; Permeability; Phenols; Piperazines; Protein Structure, Tertiary; Rats; Structure-Activity Relationship | 2017 |
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Line; Cell Survival; Chalcones; Chelating Agents; Copper; Drug Design; Flurbiprofen; Humans; Lipopolysaccharides; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nitric Oxide; Peptide Fragments; Recombinant Proteins; Structure-Activity Relationship | 2018 |
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzylamines; Blood-Brain Barrier; Cholinesterase Inhibitors; Drug Design; Humans; Kinetics; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Permeability; Protein Aggregates; Recombinant Proteins; Structure-Activity Relationship; Thiazoles | 2018 |
Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Clioquinol; Drug Discovery; Flurbiprofen; Humans; Ligands; Membranes, Artificial; Models, Molecular; Molecular Structure; Protein Conformation; Structure-Activity Relationship | 2020 |
Design, synthesis and evaluation of phthalide alkyl tertiary amine derivatives as promising acetylcholinesterase inhibitors with high potency and selectivity against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amines; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Female; Male; Membranes, Artificial; Mice; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Permeability; Protein Aggregation, Pathological; Random Allocation; Rats | 2020 |
Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line, Tumor; Cell Survival; Clorgyline; Dose-Response Relationship, Drug; Drug Design; Humans; Indans; Male; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Peptide Fragments; Protein Aggregates; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2020 |
Novel 3-benzylidene/benzylphthalide Mannich base derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Benzylidene Compounds; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Copper; Dose-Response Relationship, Drug; Electrophorus; Female; Humans; Male; Mannich Bases; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; Neuroprotective Agents; PC12 Cells; Peptide Fragments; Protein Aggregates; Rats; Structure-Activity Relationship | 2021 |
Design, synthesis and evaluation of novel dimethylamino chalcone-O-alkylamines derivatives as potential multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amines; Amyloid beta-Peptides; Animals; Antioxidants; Binding Sites; Cell Survival; Chalcone; Drug Design; Humans; Kinetics; Metals; Molecular Docking Simulation; Monoamine Oxidase; Neuroprotective Agents; PC12 Cells; Protein Aggregates; Rats; Structure-Activity Relationship | 2021 |
MAO inhibition and the effects of centrally administered LSD, serotonin, and 5-methoxytryptamine on the conditioned avoidance response in rats.
Topics: 5-Methoxytryptamine; Animals; Avoidance Learning; Brain Chemistry; Clorgyline; Injections, Intraventricular; Iproniazid; Lysergic Acid Diethylamide; Male; Monoamine Oxidase Inhibitors; Rats; Selegiline; Serotonin; Tryptamines | 1979 |
The effect of monoamine oxidase inhibitors on some arylalkylamines in rate striatum.
Topics: Amines; Animals; Clorgyline; Corpus Striatum; Iproniazid; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Phenethylamines; Rats; Selegiline; Tranylcypromine; Tryptamines; Tyramine | 1979 |
Use of pig hepatocytes to study the inhibition of monoamine oxidase by furazolidone.
Topics: Animals; Cells, Cultured; Clorgyline; Furazolidone; Hydrazines; Iproniazid; Liver; Monoamine Oxidase Inhibitors; Oxazoles; Oxazolidinones; Swine; Tyramine | 1991 |
Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors.
Topics: Animals; Brain; Clorgyline; Dose-Response Relationship, Drug; Hydrazines; Hypothalamus; Iproniazid; Male; Monoamine Oxidase Inhibitors; Phenelzine; Rats; Rats, Inbred Strains; Receptors, Adrenergic; Receptors, Serotonin; Reserpine; Selegiline; Tranylcypromine | 1986 |
Oxidative metabolism of some hydrazine derivatives by rat liver and lung tissue fractions.
Topics: 1,2-Dimethylhydrazine; Animals; Clorgyline; Cytochrome P-450 Enzyme System; Dimethylhydrazines; Hydrazines; Iproniazid; Liver; Lung; Male; Microsomes, Liver; Mitochondria, Liver; Monoamine Oxidase; Oxidation-Reduction; Pargyline; Procarbazine; Propylamines; Rats; Rats, Inbred Strains | 1986 |
Monoamine oxidase inhibitors and histamine metabolism.
Topics: Animals; Clorgyline; Histamine; Iproniazid; Male; Monoamine Oxidase Inhibitors; Oxazoles; Oxazolidinones; Rats; Selegiline; Tranylcypromine | 1980 |
Response of the isolated rabbit ciliary epithelium to adrenergic drugs following superior cervical ganglionectomy.
Topics: Animals; Cell Membrane Permeability; Ciliary Body; Clorgyline; Cocaine; Dibenzylchlorethamine; Epinephrine; Epithelium; Eye; Ganglia, Parasympathetic; Iproniazid; Isoproterenol; Norepinephrine; Phenoxybenzamine; Phenylephrine; Rabbits; Sympathomimetics | 1981 |
Inhibition of type A monoamine oxidase by coptisine in mouse brain.
Topics: Animals; Berberine; Berberine Alkaloids; Binding, Competitive; Brain; Clorgyline; Dialysis; Dose-Response Relationship, Drug; Iproniazid; Kynuramine; Male; Mice; Mice, Inbred ICR; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2001 |
(-)-Trans-epsilon-viniferin, a polyphenol present in wines, is an inhibitor of noradrenaline and 5-hydroxytryptamine uptake and of monoamine oxidase activity.
Topics: Animals; Benzofurans; Blood Platelets; Brain; Cell Line; Citalopram; Clorgyline; Dose-Response Relationship, Drug; Fluoxetine; Humans; Imipramine; Iproniazid; Isoenzymes; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Norepinephrine; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Selegiline; Serotonin; Stilbenes; Synaptosomes; Tritium; Wine | 2006 |
Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers.
Topics: Affect; Amitriptyline; Animals; Antidepressive Agents; Antimanic Agents; Benzodiazepines; Cerebral Cortex; Citalopram; Clorgyline; Cocaine; Cyclohexanols; Desipramine; Fluoxetine; Imipramine; In Vitro Techniques; Iproniazid; Lithium; Mianserin; Mirtazapine; Mitochondria; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Morpholines; Olanzapine; Pargyline; Reboxetine; Swine; Thiazepines; Valproic Acid; Venlafaxine Hydrochloride | 2010 |